ABOS
Acumen Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$2.21-1.78%
Price as of Jul 20, 2026
ABOS financials
Acumen Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $123.8M | $114.0M | $61.1M | $45.2M |
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M |
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M |
| EBITDA | -$116.9M | -$98.1M | -$51.6M | -$42.7M |
| Basic EPS | $-2.00 | $-1.71 | $-1.08 | $-1.06 |
| Diluted EPS | $-2.00 | $-1.71 | $-1.08 | $-1.06 |
| Balance sheet | ||||
| Cash & equivalents | $54.0M | $35.6M | $66.9M | $130.1M |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M |
| Stockholders’ equity | $70.4M | $181.8M | $267.0M | $188.8M |
| Total debt | $31.3M | $29.7M | $28.5M | $105.0K |
| Net debt | -$22.7M | -$5.9M | -$38.4M | -$130.0M |
| Cash flow | ||||
| Operating cash flow | -$115.5M | -$86.2M | -$43.1M | -$35.2M |
| Capital expenditure | -$88.0K | -$16.0K | -$21.0K | -$161.0K |
| Free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$73.0K | -$41.0K | $0.00 | $0.00 |